Avenzo Therapeutics

Developing the next generation of oncology therapies for patients.

Protego Biopharma

Protego Biopharma focuses on the discovery and development of small-molecule therapeutics that aim to reprogram protein folding for the treatment of various diseases. We are building upon our expertise in the proven pharmacological chaperone approach exemplified by tafamidis, the first marketed disease modifying agent for the treatment of a systemic amyloidosis. The incorporation of the latest advances in biology, chemical biology, biomarkers, structure biology, computation into our approach allows us to expand our disease scope and generate the best therapeutics possible. Our expertise allows us to focus upon generating the key preclinical data that will have clinical translation within the pharmacological chaperone approach. We have assembled a proven team of experts in discovery and development of small molecule pharmacological chaperones and protein homeostasis modulators. This team has joined forces with world-class investors and collaborators who embrace our mission.

858 therapeutics

858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology. 858 was founded by a veteran team who together bring a track record of success in pharma and biotech drug discovery. Building from our collective experience in the fields of epigenetics, single cell genomics, and innate immunity, 858 scientists are dedicated to the company’s mission to discover innovative therapeutics for the treatment of cancers that are resistant to current therapies. 858 is headquartered in the biotech hub of San Diego, CA, and maintains lab operations in both San Diego and New York City, providing proximity to leading investigators and scientific talent on both coasts of the US.

VitroLabs Inc

We cultivate authentic materials without compromise,by harnessing science and nature responsibly by partnering the most innovative minds in science and technology with the finest craftspeople to accelerate the use of cellular agriculture for good. Our first product is slaughter-free, real leather.

PrognomiQ Inc

PrognomiQ aims to generate proteomic information with high accuracy, scale and speed. This proteomic data will be complemented with genomic, metabolomic and other health information to deliver first-in-class test products that enable early disease detection and treatment. Powerful, Untapped Disease Insights Built on a Proteomics Foundation: Until now, there have been major technical and economic barriers to broad-scale proteomics analyses, leaving this rich resource of molecular information largely untapped for clinical purposes. These barriers have now been largely addressed through next generation tools that can elucidate complex proteomics at scale. Complementary Molecular Information: Genomic data has made clear contributions to researchers’ abilities to understand and more precisely treat disease, but it is has shown limited impact on early-stage disease detection. Proteomics provides direct information on the biological state of a cell, including disease at its earliest state, but proteomics data has been technically difficult to generate – until now. By complementing the new sources of proteomics data with genomics and other data, such as metabolomics, we now have the tools to generate powerful multi-omics data that will be the key to unlock the detection and treatment of disease at its earliest stages, when these diseases are most likely to be cured. Unlocking Disease Detection and Treatment with Multi-omics Data: We designed our proprietary multi-omics platform around the most robust approaches to generating proteomic, genomic and metabolomics data at scale, including the use of the Proteograph technology platform from the life science tools company Seer (NASDAQ: SEER) whom PrognomiQ spun out of in 2020.